Delaware Senator Pushes for Drug Pricing Reform Transparency for State Employees

A Delaware state senator is expressing concerns about the slow pace of drug-pricing reform by the board overseeing health benefits for over 135,000 public employees, amid new federal regulations mandating greater transparency for employer health plans.

Ray Seigfried, a Delaware State Senator and former ChristianaCare executive, introduced a resolution targeting the State Employee Benefits Committee (SEBC). This resolution aims for improved transparency in how pharmacy benefit managers (PBMs) negotiate prices, set to take effect by 2025. The importance of this measure is underscored by the projected $1.6 billion cost of Delaware's Group Health Insurance Plan by fiscal year 2027. Seigfried argues that addressing undisclosed costs within the healthcare supply chain could save millions of dollars, which aligns with new federal mandates for increased data transparency in large self-funded employer plans.

The Drive for Transparency

The SEBC has shown willingness to incorporate aspects of Seigfried's resolution into its procurement strategy for a new PBM. However, it warns that heightened transparency might increase costs or disrupt current rebate structures. SEBC Chair Neil Hockstein remarked on the ongoing challenges in the PBM market, such as confidentiality agreements and pricing information restrictions, which hinder full data transparency.

Federal and State Legislative Context

Seigfried criticized the SEBC's response, stressing the necessity for comprehensive data ownership to effectively negotiate drug prices. His viewpoint aligns with recent federal legislation that grants plan sponsors direct PBM data access. The Consolidated Appropriations Act of 2026 demands semiannual detailed drug-pricing and rebate reports from PBMs to large self-funded employer plans, including full rebate pass-through requirements. These regulations will take effect for plan years starting 30 months after enactment, expected by January 2029 for calendar-year plans.

“The 2026 reforms represent one of the most substantial changes in PBM regulation within ERISA’s history.”

— Jeffrey Hogan, Judi Group consultancy

Learning from State Precedents

State-level initiatives provide insights into these upcoming federal reforms. For instance, New Jersey and Montana have already implemented measures to enhance competitive bid opportunities for PBMs and to bolster rebate oversight. Delaware's documented market barriers reflect challenges that the federal mandate aims to mitigate. These reforms signal a shift towards much-needed transparency within the complex PBM landscape.

Implications for Insurance Professionals

The new federal reporting requirements will significantly affect self-funded plans. Brokers are encouraged to prepare by evaluating PBM contracts ahead of the 2029 deadline. Constructing robust data systems to leverage forthcoming disclosures will be essential for plan sponsors. The transparency-driven changes highlight the importance of preparation to harness regulatory benefits when they commence.

Delaware’s situation underscores the importance of preparation for regulatory changes, showcasing a broader move towards transparency that benefits both employers and plan participants. As states and federal regulations converge, insurance professionals must stay agile, ensuring they are ready to adapt and capitalize on new industry standards.